Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBLED: Foliglurax in Parkinson's Disease
NCT03162874Phase 2Completed
- Sponsor
- Lundbeck
- Start
- Jul 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of foliglurax in Parkinson's disease (PD) (3 arms), sponsored by Lundbeck. Primary endpoint: Change from baseline to end of Treatment Period in the daily awake OFF time at 28 days. Started Jul 2017; status: completed.
02
Drugs
foliglurax
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03162874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03162874.